Publication | Closed Access

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

Autoimmune DiseaseIpilimumab-triggered AutoimmunityImmunologyMelanomaCell DeathInhibitor TherapyAutoimmunityImmune Checkpoint InhibitorImmunomodulationImmunotherapyMedicineRadiation OncologyAdvanced Melanoma